在充分评估患者病情、完善术前准备并组织多学科讨论后,手术团队制定了周密的手术方案。整个手术 过程仅用时不足半小时,且未出现相关并发症,手术取得圆满成功。目前,王阿姨已恢复出院。 此次荣成市人民医院成功开展山东省首例经皮间隔心肌射频消融术,不仅为肥厚型梗阻性心肌病患者提 供了新的治疗选择,也为山东省心血管疾病微创治疗技术的发展积累了宝贵经验。未来,荣成市人民医院 心内二科将继续加强与国内顶尖医院的学术交流与技术合作,不断引进前沿技术,为区域内心血管疾病患 者带来更多福音。 近日,荣成市人民医院心内二科团队在中国医学科学院阜外医院专家指导下,成功为71岁患者实施山东省 首例经皮间隔心肌射频消融术,这一突破性手术不仅为患者解除了多年的病痛困扰,更填补了山东省在肥 厚型梗阻性心肌病微创治疗领域的技术空白,标志着威海地区心血管疾病精准治疗水平迈上新台阶。 (李煜) 71岁的王阿姨3年前无明显诱因出现胸痛症状,在外院行冠脉造影检查提示冠脉狭窄约40%,此后长期规律 服用相关药物控制病情。然而今年10月中旬,王阿姨的胸痛症状再次发作,且发作频率逐渐增加,严重影响 了正常生活。为寻求进一步治疗,她来到荣成市人民医院心内二科就 ...

Core Insights - AMT Medical has developed the ELANA seamless heart bypass technology, allowing surgeries without chest opening, thus reducing patient trauma and recovery time [1][4][16] Industry Overview - Cardiovascular diseases (CVDs) remain a leading cause of death globally, with approximately 18.5 million deaths in 2023, projected to rise to 24 million by 2030 [2] - Traditional coronary artery bypass grafting (CABG) surgeries face significant challenges, including chest trauma, recovery difficulties, and high medical costs [2][3] Technology Advantages - The ELANA system utilizes laser-assisted vascular connections and specialized clips, enabling surgeries without sutures and heart-lung machines, thus maintaining blood circulation during procedures [4][5][7] - The system significantly reduces stroke risk from 3%-5% in traditional surgeries to less than 1% with ELANA, and lowers anastomosis leak rates from 8%-12% to below 2% [9][10] Market Potential - The global minimally invasive surgery market is projected to grow from $62 billion in 2023 to $130 billion by 2030, with cardiovascular devices accounting for over 30% of this market [3] - AMT's technology is adaptable for various surgical methods and has potential applications in peripheral vascular bypass and heart valve repair, expanding its market reach [10][15] Financial Backing - AMT has raised a total of €24.5 million (approximately $26 million) in funding, including a recent €22 million Series B round to accelerate CE certification and clinical trials in the U.S. [11][12][13] Future Plans - The company aims to achieve CE certification by 2026 and initiate FDA approval processes in 2027, targeting to reduce surgical costs by an additional 30% and benefit one million patients annually [15][16]